Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label tolerability study of AVANZ Dermatophagoides mixture immunotherapy
2011-002017-11Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Jul 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of House dust mite allergen extract in allergic rhinoconjunctivitis (ARC), house dust mite allergy, allergic asthma, sponsored by ALK-Abelló. Started Jul 2011; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)house dust mite allergyallergic asthma
Beyond the preview
Go deeper on 2011-002017-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002017-11.